Back to articles

Beyond Barriers: Cadonilimab's Universal Attack on Cervical Cancer Unveiled at ASCO 2025

Leila Cohen•Jun 16, 2025
A dynamic, abstract rendering of the dual-action cadonilimab antibody engaging and neutralizing cancer cells, with a diverse group of hopeful women subtly hinted in the background.
  • Universal Efficacy: Cadonilimab demonstrates significant survival benefits in advanced cervical cancer, irrespective of PD-L1 status or prior treatments.
  • ASCO 2025 Spotlight: New subgroup analysis from the COMPASSION-16 trial, presented orally, reinforces cadonilimab's groundbreaking potential.
  • New Standard of Care?: This first-in-class PD-1/CTLA-4 bispecific antibody is poised to redefine treatment for women globally.

The fight against advanced cervical cancer has a powerful new champion. Akeso, Inc. (9926.HK) electrified the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting with an oral presentation detailing a crucial subgroup analysis from the Phase III COMPASSION-16 trial6, 8. This study, the largest of its kind in an Asian population for first-line cervical cancer5, 8, evaluates cadonilimab, a pioneering first-in-class PD-1/CTLA-4 bispecific antibody.

The latest data confirms cadonilimab's profound impact, demonstrating significantly improved progression-free survival (PFS) and overall survival (OS) across a wide spectrum of patients. Whether facing varying PD-L1 expression levels, having undergone prior chemoradiotherapy, used bevacizumab, or differing in age, women experienced consistent, life-extending benefits8. This is a monumental leap, particularly as cadonilimab shows robust efficacy in both PD-L1-positive and PD-L1-negative populations—a critical distinction where other immunotherapies may falter8.

These findings, building on initial results previously published in The Lancet and presented at the 2024 IGCS Global Meeting8, solidify cadonilimab's immense clinical value. Already approved in China for various indications, including first-line advanced cervical cancer, cadonilimab is not just a drug; it's a beacon of hope, promising to elevate the standard of care and make a lasting impact on global women's health8.

References

  1. ascopubs.org
  2. ascopubs.org
  3. www.sitcancer.org
  4. www.tandfonline.com
  5. www.esmo.org
  6. ground.news
  7. www.onclive.com
  8. www.biospace.com

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.